|
BRPI0313202A8
(pt)
|
2002-08-05 |
2016-08-16 |
Atugen Ag |
Formas adicionais para interferir com as moléculas de rna
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
ATE485394T1
(de)
*
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
US7459547B2
(en)
*
|
2003-06-02 |
2008-12-02 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
|
ES2485848T3
(es)
*
|
2003-09-12 |
2014-08-14 |
University Of Massachusetts |
ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
WO2007022470A2
(en)
*
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
|
EP4082551A1
(en)
|
2006-08-08 |
2022-11-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
EP2323695B1
(en)
|
2008-08-19 |
2018-12-05 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
CN102325534B
(zh)
*
|
2008-12-18 |
2016-02-17 |
戴瑟纳制药公司 |
延长的dicer酶底物和特异性抑制基因表达的方法
|
|
US11408003B2
(en)
|
2008-12-18 |
2022-08-09 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US20120022142A1
(en)
*
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
EP2756845B1
(en)
*
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
CN102575254B
(zh)
|
2009-04-03 |
2015-03-04 |
戴瑟纳制药公司 |
利用不对称双链rna特异性抑制kras的方法和组合物
|
|
CA2762524A1
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
AU2010259295B2
(en)
|
2009-06-10 |
2015-05-07 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (VIGS) for functional analysis of genes in cotton.
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011072082A2
(en)
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
WO2012006241A2
(en)
|
2010-07-06 |
2012-01-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
|
|
DK3587579T3
(da)
|
2010-07-06 |
2021-04-26 |
Dicerna Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
CN103492572A
(zh)
|
2011-03-03 |
2014-01-01 |
夸克医药公司 |
用于治疗肺疾病和损伤的组合物和方法
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
SG10201604726YA
(en)
|
2011-06-10 |
2016-07-28 |
Temasek Life Sciences Lab Ltd |
Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
ES2897565T3
(es)
|
2011-10-18 |
2022-03-01 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
HK1200191A1
(en)
|
2011-11-18 |
2015-07-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
NZ700075A
(en)
|
2012-02-24 |
2016-05-27 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10100321B2
(en)
|
2012-04-19 |
2018-10-16 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
CN105189541A
(zh)
|
2012-12-14 |
2015-12-23 |
戴瑟纳制药公司 |
用于通过双链rna特异性抑制ckap5的方法和组合物
|
|
HUE055044T2
(hu)
|
2013-03-14 |
2021-10-28 |
Translate Bio Inc |
MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
|
|
KR102205278B1
(ko)
|
2013-03-14 |
2021-01-22 |
다이서나 파마수이티컬, 인크. |
음이온성 약제를 제형화하는 방법
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PL3444350T3
(pl)
|
2013-07-03 |
2022-03-21 |
Dicerna Pharmaceuticals, Inc. |
Sposoby i kompozycje do specyficznego hamowania alfa-1 antytrypsyny przez dwuniciowy rna
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
RS61892B1
(sr)
|
2013-12-27 |
2021-06-30 |
Dicerna Pharmaceuticals Inc |
Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
|
|
AU2015330670B2
(en)
|
2014-10-10 |
2022-01-06 |
Novo Nordisk Health Care Ag |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
WO2016183009A2
(en)
|
2015-05-08 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
|
|
JP7073109B2
(ja)
*
|
2015-07-02 |
2022-05-23 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
|
|
EP3506909B1
(en)
|
2016-09-02 |
2022-06-29 |
Dicerna Pharmaceuticals, Inc. |
4'-phosphate analogs and oligonucleotides comprising the same
|
|
JP7208911B2
(ja)
*
|
2017-10-11 |
2023-01-19 |
日東電工株式会社 |
核酸分子発現の調節
|
|
CN111448319B
(zh)
|
2017-10-13 |
2024-05-17 |
诺和诺德保健股份有限公司 |
用于抑制ldha表达的方法和组合物
|
|
MY201698A
(en)
|
2017-10-20 |
2024-03-13 |
Dicerna Pharmaceuticals Inc |
Methods for treating hepatitis b infection
|
|
US11813280B2
(en)
|
2018-01-05 |
2023-11-14 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
JP2021511042A
(ja)
|
2018-01-16 |
2021-05-06 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ａｌｄｈ２発現を阻害するための組成物及び方法
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
EP3846797A4
(en)
|
2018-09-04 |
2022-06-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
USE OF DELTA-TOCOTRIENOL TO TREAT CANCER
|
|
US11452738B2
(en)
|
2019-01-04 |
2022-09-27 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
|
|
AU2020221892A1
(en)
|
2019-02-12 |
2021-08-19 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of CYP27A1
|
|
US20220154189A1
(en)
|
2019-03-29 |
2022-05-19 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
CA3135402A1
(en)
|
2019-04-04 |
2020-10-08 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
KR20220004675A
(ko)
|
2019-05-03 |
2022-01-11 |
다이서나 파마수이티컬, 인크. |
단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자
|
|
MX2022002533A
(es)
|
2019-08-30 |
2022-06-02 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos modificados con ligandos 2', síntesis de estos y compuestos intermedios de estos.
|
|
IL291841A
(en)
|
2019-10-02 |
2022-06-01 |
Dicerna Pharmaceuticals Inc |
Chemical modifications of small interfering rna with minimal fluorine content
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
IL296549A
(en)
|
2020-03-18 |
2022-11-01 |
Dicerna Pharmaceuticals Inc |
Compositions and methods for inhibiting angptl3 expression
|
|
JP2023538284A
(ja)
|
2020-08-04 |
2023-09-07 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッド |
Ｐｌｐ１発現を阻害するための組成物及び方法
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
CA3187220A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
|
JP7476422B2
(ja)
|
2020-08-05 |
2024-04-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ｌｐａ発現を阻害するための組成物及び方法
|
|
JP2023536999A
(ja)
|
2020-08-05 |
2023-08-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎患者のオリゴヌクレオチド処置
|
|
WO2022218941A2
(en)
|
2021-04-12 |
2022-10-20 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for inhibiting ketohexokinase (khk)
|
|
KR20230171431A
(ko)
|
2021-04-14 |
2023-12-20 |
다이서나 파마수이티컬, 인크. |
Pnpla3 발현을 조절하기 위한 조성물 및 방법
|
|
CA3213775A1
(en)
|
2021-04-19 |
2022-10-27 |
Utsav SAXENA |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
|
AR125992A1
(es)
|
2021-05-28 |
2023-08-30 |
Novo Nordisk As |
Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
|
|
CN117897483A
(zh)
|
2021-08-25 |
2024-04-16 |
戴瑟纳制药公司 |
用于抑制α-1抗胰蛋白酶表达的组合物和方法
|
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for treatment of hbv
|
|
US12234456B2
(en)
|
2021-12-01 |
2025-02-25 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating APOC3 expression
|
|
KR20250005108A
(ko)
|
2022-04-15 |
2025-01-09 |
다이서나 파마수이티컬, 인크. |
Scap 활성을 조절하기 위한 조성물 및 방법
|
|
JP2025516677A
(ja)
|
2022-05-12 |
2025-05-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ｍａｐｔの発現を阻害するための組成物及び方法
|
|
KR20250024534A
(ko)
|
2022-05-13 |
2025-02-18 |
다이서나 파마수이티컬, 인크. |
Snca 발현을 억제하기 위한 조성물 및 방법
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
TW202511486A
(zh)
|
2023-07-28 |
2025-03-16 |
美商黛瑟納製藥公司 |
用於程式化死亡配體受體（ｐｄ－ｌ１）表現之組成物和方法
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
US20260055414A1
(en)
|
2024-08-21 |
2026-02-26 |
Novo Nordisk A/S |
Compositions and methods for inhibiting xdh expression
|